Literature DB >> 15362669

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.

Anne-Geneviève Marcelin1, Jacques Reynes, Sabine Yerly, Nadine Ktorza, Michel Segondy, Jean-Claude Piot, Jean-François Delfraissy, Laurent Kaiser, Luc Perrin, Christine Katlama, Vincent Calvez.   

Abstract

We analysed the genetic changes in gp41 in a population of 30 heavily pretreated HIV-1-infected patients failing on a T-20-containing salvage therapy. This study confirms the key role of the number of drugs presumed to be still effective associated with T-20 in the magnitude of the virological response. Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362669     DOI: 10.1097/00002030-200406180-00015

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

Review 1.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.

Authors:  Michelle Marcial; Jing Lu; Steven G Deeks; Rainer Ziermann; Daniel R Kuritzkes
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 4.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

5.  Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).

Authors:  V A Morozov; A V Morozov; S Lagaye
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

Review 6.  Enfuvirtide: a review of its use in the management of HIV infection.

Authors:  Vicki Oldfield; Gillian M Keating; Greg Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.

Authors:  Vincent Marconi; Sebastian Bonhoeffer; Roger Paredes; Jing Lu; Rebecca Hoh; Jeffery N Martin; Steven G Deeks; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-15       Impact factor: 3.731

Review 8.  HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Authors:  Michele W Tang; Robert W Shafer
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

9.  Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load.

Authors:  Naveen K Vaidya; Libin Rong; Vincent C Marconi; Daniel R Kuritzkes; Steven G Deeks; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2010-11-24       Impact factor: 4.475

10.  Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide.

Authors:  Adam S Dingens; Dana Arenz; Julie Overbaugh; Jesse D Bloom
Journal:  Viruses       Date:  2019-05-15       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.